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Existing animal models for Rat Cytomegalovirus (RCMV) infections
require immunosuppression, induced by total body irradiation, to allow for
maximal viral replication. Since we are interested to study antiviral compounds
with immunomodulatory effects, we developed an RCMV model in the
immunocompetent rat.
Five different rat strains, Lewis, AO, BBDP, BN and F344, were infected
intraperitoneally with either 1x 106 or 1x 107 pfu of free virus, without irradiation.
Rats were sacrificed at 4 or 8 weeks post infection. Virus titres in salivary gland as
determined with plaque assays, were highest in F344 rats and lowest in BN rats.
An ELISA was developed to quantify titres and isotype of RCMV-specific
antibodies in sera of the infected rats. All five rat strains developed serum
antibodies against RCMV, with highest titres detectable at 8 weeks post infection.
The RCMV-specific total Ig titres were highest in BN and F344 rats. Furthermore,
at 8 weeks post infection, only BN and F344 rats had substantial RCMV-specific
IgG titres. The sera of F344 and BN rats had an equal virus neutralising activity in
vitro, but virus titres in BN rats were considerably lower as compared to F344 rats
in vivo.
In conclusion, of the five strains that were tested in our model for RCMV
infection in immunocompetent rats, the F344 strain was most susceptible to viral
replication. Thus, F344 is the most suitable strain to test antiviral compounds in
immunocompetent rats. In the BN strain a quick humoral response can inhibit viral
dissemination during primary infection. A phenomenon that is in contrast with the
current opinion that antibodies only play a limited role during primary infection.
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INTRODUCTION
Cytomegalovirus (CMV) is a member of the ß-herpes virus family. It
causes a latent and persistent infection, and the virus can reactivate under
circumstances of immunosuppression. In immunocompetent individuals, primary
infections with human cytomegalovirus (HCMV) generally pass unnoticed due to
the lack of clinical symptoms. However, in the immunocompromised host primary
infections and reactivations of the virus cause severe morbidity or mortality 10,14,15.
In order to develop an animal model to examine antiviral compounds for CMV
infections, we adapted a Rat Cytomegalovirus (RCMV) model, as previously
described by Stals et al. 13. In this animal model, total body irradiation (TBI) is
used as a means of immunosuppression, in order to allow for maximal viral
replication, which is important to sensitively determine virostatic effects of
antiviral compounds. Since we want to study compounds with possible
immunomodulatory effects, an RCMV infection in immunocompetent rats was a
prerequisite.
We hypothesised that rat strains would sufficiently differ in their immune
response, that one strain would be susceptible enough to viral replication without
immunosuppression by TBI. Therefore, the presence of strain specific differences
in virus production in immunocompetent rats, after infection with RCMV, was
studied using 5 different rat strains. We anticipated that differences in viral load
would be reflected in virus titres in salivary glands and spleen as determined by
plaque assay and by histochemistry. In addition, an ELISA was developed to
detect and quantify in the titre and subtype of antibodies (total Ig, IgM and IgG)
directed against RCMV antigens in sera of infected rats. Furthermore, sera of
infected rats were tested for their virus neutralising properties in vitro, in order to





Virus stocks were produced as described earlier 3. In brief, male specified
pathogen free AO rats (Harlan, Zeist, The Netherlands), 8 weeks of age, received
total body irradiation (5 Gy) and were infected i.p. with 106 plaque forming units
(pfu) of the Maastricht strain RCMV, 6 h post TBI. Animals were held at the
Central Animal Facility of the Groningen University and received standard chow
and water ad libitum. Four weeks after administration of virus, rats were sacrificed
and the submandibular salivary glands were removed. The salivary glands were
homogenised, sonified and centrifuged as described earlier. Virus stocks were
stored at –80°C. A plaque assay was used to quantify the titre of virus in the
homogenate. All animal experiments described in this study were approved by the
local Ethical Board for Animal Studies.
Production of antigen extract.
The rat lung fibroblast cell line RFL-6 (ECACC, UK) was cultured in
DMEM/HAM F12 (Biowhittaker Europe, Verviers, Belgium), supplemented with
20% Fetal Calf Serum (FCS) (Brunschwig Chemie, Maarssen, The Netherlands),
200mM L-glutamin (Gibco BRL, Paisley, Scotland), 60 µg/ml gentamycin
sulphate (Gibco BRL) and 1% Non Essential Amino Acids (Gibco BRL) at 37°C,
5% CO2 and 100% relative humidity. The cells were cultured in 162 cm2 culture
flasks (Corning Costar, Cambridge, UK). One passage prior to infection, cells
were serum starved, until maintained on culture medium with 5% FCS.
Subsequently, virus was added at a multiplicity of infection (MOI) of 0.1.
Infection was allowed to proceed until maximal cytopathic effect was
achieved (usually up to 10 days post infection). Cells were detached using a cell
scraper and collected by centrifugation (15 mins, 2500 rpm). The infected cells
were lysed in lysis buffer, consisting of 500mM NaCl, 100mM Tris/HCl pH 8.0
and 1% Nonidet P40, and homogenised by sonication. This extract was diluted
with 0.1 M carbonate buffer (pH 9.6), 0.01% sodium azide, and stored at 4°C until
use.
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Infection of rats with RCMV.
Male rats, at the age of 4 weeks, of 5 different strains with 3 animals in
each group (BN, F344 Fischer, AO, Lewis and BBDP, obtained from Harlan,
Zeist, The Netherlands) were injected i.p. with 106 or 107 pfu of the AO virus
stock. For reference, a group of Lewis rats (n=3) were irradiated (5 Gy) and
infected i.p. with 106 pfu RMCV 6 hrs after irradiation. At 4 or 8 weeks post
infection (p.i.), the animals were sacrificed. Sera were obtained by heart puncture
and the submandibular salivary glands and spleen were removed for determination
of the virus titres, using the plaque assay, and for histology. Furthermore, the
pancreas, heart, lung, liver, colon and kidney were removed for histological
evaluation.
Histochemical evaluation.
Organs were fixed in 3.7% formalin solution in Phosphate Buffered Saline
(PBS, pH 7.4) for 24 h, and subsequently embedded in paraffin according to
standard methods. Sections of 4µm were incubated with monoclonal antibody
(Mab) 8 or 35 8 to assess the presence of viral antigens. Mab 8 was used to detect
Early antigens, whereas Mab 35 detects late antigens. Subsequently, Rabbit-anti-
Mouse peroxidase (DAKO, Glostrup, Denmark) was added and detection was
achieved using amino-ethyl-carbazole (Sigma, St. Louis, MO). Counterstaining
was performed with hematoxillin. In addition, sections of 4 µm were stained with
hematoxillin and eosin, according to standard methods.
Quantification of virus titres using plaque assay.
The RCMV titres in salivary gland and spleen homogenates were
quantified using a plaque assay as described before 2. In brief, tenfold serial
dilutions of tissue homogenates were added to a confluent layer of Rat Embryonal
Fibroblasts (REF) 13, cultured in 24-wells plates, and incubated for 1 h.
Subsequently, the inocula were removed and replaced by culture medium
supplemented with 1% hydroxypropyl methyl cellulosum (Brocacef, Maarssen,
The Netherlands). Plates were cultured at 37°C and 5% CO2 for 7 days, followed
by fixation of the cells with 3.7% formalin in PBS. The cells were stained with
methylene blue and the number of virus plaques was evaluated microscopically.
The virus titre was expressed as plaque forming units (pfu) per gram tissue.
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Detection of anti-RCMV antibodies in sera using ELISA.
Antigen extracts were coated in 96-well plates (Corning Costar,
Cambridge, UK) in 0.1 M Carbonate buffer, pH 9.6 at room temperature for 16 h.
The plates were washed five times with wash buffer (0.015M NaCl, 0.05 M
Tris/HCl and 0.05% Tween-20, final pH 8.0). Twofold serial dilutions of sera,
starting at a tenfold dilution, in incubation buffer (0.05M Tris/HCl, 0.05% Tween-
20 and 2% bovine serum albumin) were added to a final volume of 100 µl per well
and incubated at room temperature for 1 h. Subsequently, plates were washed with
wash buffer, and 100 µl Rabbit-anti-Rat total Ig-HRP or Goat-anti-Rat IgG-HRP
(both DAKO), diluted 4000-fold in incubation buffer, was added to each well. For
the detection of anti-RCMV-IgM antibodies, biotin labelled anti-Rat IgM
(Pharmingen, Woerden, The Netherlands) was added, 1000-fold diluted in
incubation buffer. In the latter case, streptavidin-HRP (DAKO) was subsequently
added in a 1000-fold dilution in incubation buffer. The plates were incubated at
room temperature for 30 min. Staining was performed with 100µl of ortho-
phenylene-diamine (OPD) solution (Sigma) per well. The staining reaction was
stopped by adding 100 µl of 1 M H2SO4 to each well. Finally, the optical density
at 490nm was measured with a plate reader, equipped with SOFTMAX software.
Extinctions were plotted against the dilutions of the sera.
RCMV-specific antibody titres were calculated by determining the
maximal dilution of the serum at which the OD490nm exceeded 0.2 U above the
blank values.
Virus neutralisation experiments.
RFL-6 fibroblasts were seeded in 24-wells plates and grown in culture
medium as described earlier, until confluency was reached. Sera of the rats,
obtained at 8 weeks after infection and from non-infected animals, were heated at
56°C for 15 min. to inactivate complement. Twofold serial dilutions of these sera,
between 20-160-fold dilutions, were added to the wells and incubated at 37°C and
5% CO2 for 15 min. After incubation, 100 pfu of RCMV salivary gland
homogenate was added to each well and incubated at 37°C and 5% CO2 for 1 h.
Subsequently, virus and sera were removed and the cell layer was fixed with
culture medium, supplemented with 1% of hydroxypropyl methyl cellulosum. At 7
d.p.i., the cells were fixated and stained in as described for the plaque assay. The
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number of plaques obtained after addition of virus with serum of non-infected
animals was set at 100%.
Statistical analyses.
Two-tailed Mann-Whitney U tests were performed to detect significant
differences in antibody titres between the different rat strains. Differences where
considered significant when p < 0.05.
RESULTS
Quantification of virus titres using plaque assays.
The virus titres determined in salivary glands and spleens of the different
rat strains at 4 and 8 weeks p.i. are shown in Table 1. Of all five rat strains tested,
virus titres in salivary glands were maximal at 4 weeks and decreased at 8 weeks
p.i. The virus titres were highest in the irradiated Lewis strain. From all the
immunocompetent rat strains tested, virus titres were highest in the F344 rats. In
contrast, virus was never detected in the spleens of the all the immunocompetent
rat strains tested. Injection of a higher amount of virus (107 pfu / animal) did not
lead to increased virus titres detectable in the salivary glands at 4 or 8 weeks p.i.
Surprisingly, a tendency for lower virus titers in the group with the highest amount
of injected virus was observed.
1x 106 pfu RCMV 1x 107 pfu RCMV
Strain 4 wks p.i. 8 wks p.i. 4 wks p.i. 8 wks p.i.
BN 1.2±2 x 104 1.7±2 x 104 3.5±3 x 103 15**
F344 5.1±4 x 106 4.7±0.5 x 105 4.7±0.5 x 105 6.2±2 x 104
AO 2.6±2 x 105 4.7±2 x 104 1.6±1 x 105 1.6±2 x 104
BBDP N.D. 5.0 ± 104 1.3±0.2 x 106* N.D.
Lewis 4.0±0.1 x 105 - - -
Lewis + TBI 1.2± 0.05x 108 - - -
Table 1: Virus titres in salivary glands of RCMV-infected rats. RCMV titres, expressed as pfu/
gram tissue, as calculated from the results of the plaque assay. ND: Not Determined, -: not tested,
*  :Animals were sacrificed at 2 weeks p.i.,**: n=2.
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Histochemical evaluation.
RCMV infection in the salivary glands can be assessed with HE-staining,
by the detection of distinctive “owl's eye” cells in the secretory tubules 6. A typical
representation of CMV-infected cells in a salivary gland is shown in Fig. 1. Not
only were these “owl’s eyes” readily detected in the irradiated Lewis strain glands
(> 50 per 5 microscopic fields at 200x magnification), but also in the glands of the
immunocompetent strains, albeit at a lower frequency (< 10 per 5 microscopic
fields at 200x magnification). Immunohistochemical staining of the organs of both
irradiated and non-irradiated rats with Mab 8 or Mab 35, did not show any signs of
viral replication in other organs than the salivary glands of the various rat strains.
This observation was in contrast to infections described earlier in irradiated rats,
where viral replication could be demonstrated in organs such as liver, spleen and
lung 13.
Fig. 1: Hematoxillin Eosin staining of a salivary gland section of a RCMV-infected, irradiated
Lewis rat. Characteristic enlargement of the infected cells (“owl's eyes”, indicated with arrow) are clearly
visible. Section shown is of a irradiated Lewis rat, 4 weeks after infection. Magnification is 100 x.
Detection of RCMV-specific antibodies.
An ELISA was developed to quantify RCMV specific antibodies in sera of
infected rats. As a negative control, sera of infected animals were incubated with a
coated protein extract of non-infected fibroblasts. None of the serum samples from
Chapter 7 147
all five strains tested, showed binding of immunoglobulins to this extract.
Furthermore, serum antibodies of non-infected animals did not bind to the protein
extract of infected fibroblasts (data not shown), whereas serum antibodies of
infected animals did show binding to the protein extract of infected fibroblasts.
Both controls indicated that we were able to specifically detect antibodies directed
against RCMV antigens.
Antibodies against RCMV-encoded antigens could be detected in the sera
of all rat strains that were tested (Fig. 2). Rats infected with 106 pfu of RCMV
showed similar antibody titres as rats infected with 107 pfu. Thus the titre of
RCMV-specific antibodies was not affected by the amount of injected virus. In all
animals, RCMV-specific antibody titres were considerably higher at 8 weeks p.i.
as compared to 4 weeks p.i. Furthermore, at 8 weeks p.i. RCMV-specific antibody
titres in BN and F344 rats were considerably higher than in AO, Lewis and BB
rats.


















































Fig. 2: RCMV antibody titres in sera of RCMV-infected rats. Five different rat strains were infected
with RCMV. At 4 and 8 weeks p.i., animals were sacrificed and antibody titres were determined using the RCMV-
ELISA. Antibody titres in BN rats were significantly higher as compared to titres in all other strains, both at 4
and 8 weeks post infection (p < 0.05, Mann-Whitney U).
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In order to study the antibody response in more detail, a distinction
between RCMV specific IgM- and IgG-titres was made. RCMV-specific IgM
antibodies were only detectable at low levels in sera of non-irradiated Lewis rats at
4 weeks p.i. (data not shown). RCMV-specific IgG titres were maximal in BN and
F344 rats (Fig.3). In AO, BBDP and Lewis rats no substantial RCMV-specific IgG
titres could be detected.















































Fig.3: RCMV-specific IgG titres in sera of RCMV-infected rats. Rat IgG-specific antibodies were used in the
RCMV-ELISA to determine RCMV-specific IgG-titres of the different rat strains that were infected with RCMV.
At 4 and 8 weeks p.i. BN rats had significantly higher IgG titres as compared to all other strains (P < 0.05,
Mann-Whitney U). At 8 weeks p.i., also F344 rats had developed a considerable IgG titre.
Neutralisation experiments.
Virus neutralisation assays were performed to assess whether the anti-
RCMV antibodies in the sera of infected rats had virus-neutralising properties.
Since antibody titres were maximal at 8 weeks p.i., only these sera were tested.
The results of the neutralisation experiments are shown in Fig. 4. Sera of non-
infected rats were not able to neutralise RCMV in vitro (not shown). The tested
sera of all the infected rat strains had virus neutralising properties at the lowest
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dilution tested. However, at higher dilutions, only the sera of BN and F344 rats
retained substantial virus neutralising capacities. Interestingly, the virus
neutralising activity of F344 rats in vitro was evident, whereas in vivo these
animals had the highest virus titres.























Fig. 4: Virus neutralising properties of RCMV-specific antibodies in sera of infected rats. At low
dilutions, sera of all tested rat strains exerted virus neutralising activity in vitro. However, at high dilutions, only
BN and F344 sera retain virus neutralising capacities.
DISCUSSION
In this study, 5 different rat strains were infected with 2 doses of RCMV
to determine which strain was most susceptible to RCMV-infection without prior
Total Body Irradiation (TBI). The virus titres in salivary glands were highest in
F344 rats both at 4 and 8weeks p.i. In contrast, virus titres were 10-100 fold lower
in the BN strain. Furthermore, these strain specific differences were also reflected
in RCMV-specific antibody production. At 4 weeks p.i., antibody titres were
significantly lower in the F344, AO, BBDP and Lewis strains as compared to BN
rats (p < 0.05). At 8 weeks p.i. antibody titres in AO, BBDP and Lewis strains
were significantly lower as compared to both BN and F344 rats (p < 0.05). In
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addition, only in the BN and F344 strains could a specific IgG production against
RMCV-antigens be detected, both at 4 and 8 weeks p.i. IgM titres, albeit low,
were only detectable in Lewis rats at 4 weeks p.i. Since we did not use a capture
ELISA, it is conceivable that the ELISA we used resulted in an underestimation of
the IgM titres. IgG, which is also present in the tested sera, has a higher affinity
than IgM antibodies and is likely to compete with IgM for binding to the exposed
RCMV-antigens.
The viral antigenic determinants that are reactive with the RCMV-
antibodies have not been determined, but Mab 8 and Mab 35 reactivity indicates
the presence of both early and late antigens in the extract of infected cells (data not
shown) 8. In humans, antibodies directed against various HCMV proteins,
including viral glycoproteins have been shown to possess virus neutralising
activity 9,11,12. This neutralising activity could already be detected during primary
infection 1,5,7.
In our study, the neutralising activity of anti-RCMV antibodies was also
investigated. The sera of all tested rat strains possessed virus neutralising activity
in vitro. Sera of AO and Lewis rats however, rapidly lost their neutralising activity
after further dilution. At 8 weeks post infection, the virus neutralising activity was
highest in the BN and F344 strains, which also had the highest RCMV-specific
antibody titres. Interestingly, at both 4 and 8 weeks p.i., the virus titres in salivary
glands of the F344 rats were the highest of all tested strains, whereas the virus
titres of the BN rats were the lowest of all tested strains. However, total Ig as well
as IgG titres in BN-rats were significantly higher as compared to F344 rats at 4
weeks p.i. and at 8 weeks p.i. (p < 0.05 and 0.01, respectively). From these data,
we hypothesise that the low virus titres in the salivary glands of the infected BN
rats result from the rapid development of virus neutralising antibodies. At 8 weeks
p.i., when F344 rats have almost reached similar antibody titres as compared to the
BN rats, RCMV replication is already diminishing, and the virus enters latency. At
this time point, high titres of RCMV-specific antibodies will be less efficient in the
clearance of virus.
Jonjic et al. 4 demonstrated that antibodies were more important in the
prevention of viral disease after reactivation of the virus. One could hypothesise
that the development of virus specific, neutralising antibodies during primary
infection takes too much time. Therefore, during the early phase of primary
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infection, virus specific antibodies may not optimally inhibit viral dissemination.
This will lead to relatively high virus titres, at least in salivary glands, during early
phases of primary infection. Our data however, suggest that antibodies play a role
in the clearing of primary viral infections in a strain specific manner. The BN
strain, which is capable of mounting a quick humoral response, is able to limit
primary RCMV infection.
In conclusion, we have demonstrated strain specific differences in
susceptibility to RCMV-infection in immunocompetent rats. The F344 strain is the
most sensitive to viral infection, making this strain the most suitable for testing of
antiviral immunomodulatory therapeutics. Furthermore, strain specific differences
in the humoral response against RCMV-antigens have been detected, using a
newly developed ELISA-method. Of all the strains tested, the BN strain was the
quickest in the humoral response, leading to the highest RCMV-specific antibody
titres. Finally, the quick humoral response and the low virus titres in this strain
indicate that virus-specific antibodies are able to play an important role during in
clearing of primary viral infections.
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